» Articles » PMID: 21279331

Effect of Dronedarone on Na+, Ca2+ and HCN Channels

Overview
Specialty Pharmacology
Date 2011 Feb 1
PMID 21279331
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies showed that amiodarone causes state-dependent inhibition of Na(+) channels thereby mediating an atrial-selective drug effect. The aim of the present study was to investigate the impact of the new antiarrhythmic compound dronedarone on Na(+), Ca(2+) and hyperpolarization-activated cyclic nucleotide-gated ion channels. Monophasic action potentials (MAP) and effective refractory period (ERP) were studied in arterially perfused left atria and ventricular wedge preparations of the pig. Fast Na(+) and Ca(2+) currents in isolated guinea pig ventricular myocytes as well as human HCN4 channels expressed in Chinese hamster ovary (CHO) cells were investigated with the patch-clamp technique. In left atrial epicardial tissue, dronedarone (3 μM) had no effect on the MAP duration, but the drug caused a significant prolongation of the ERP from 145 ± 9 to 184 ± 17 ms (n = 6; p < 0.05). In guinea pig ventricular myocytes, dronedarone exhibited a state-dependent inhibition of the fast Na(+) channel current with an IC(50) of 0.7 ± 0.1 μM, when the holding potential (V (hold)) was -80 mV. The maximal block at the highest concentration used was 77 ± 8%. In contrast, when V (hold) was -100 mV, inhibition with 10 μM dronedarone was only 9 ± 3% (n = 7). Dronedarone blocked Ca(2+) currents elicited by rectangular pulses at V (hold) = -40 mV with an IC(50) value of 0.4 ± 0.1 μM (maximal block by 10 μM dronedarone, 80 ± 6%), whereas at V (hold) = -80 mV, 10 μM dronedarone blocked only 20 ± 6% (n = 4) of the current. Applying an action potential clamp (V (hold) = -80 mV) yielded an IC(50) of 0.4 ± 0.3 μM. Human HCN4 channels expressed in CHO cells were blocked by dronedarone with an IC(50) of 1.0 ± 0.1 μM. Inhibition of fast Na(+) and Ca(2+) channels by dronedarone depends on the cell's resting membrane potential (state-dependent block) favouring an atrial-selective mode of action. Besides fast Na(+) and Ca(2+) channels, dronedarone also inhibits HCN4 currents. This might contribute to the clinically observed reduction in heart rate seen in patients in sinus rhythm after dronedarone treatment.

Citing Articles

Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option.

Kraft M, Buscher A, Wiedmann F, Lhoste Y, Haefeli W, Frey N Front Pharmacol. 2021; 12:638445.

PMID: 33897427 PMC: 8058608. DOI: 10.3389/fphar.2021.638445.


Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.

Holmes A, Saxena P, Kabir S, OShea C, Kuhlmann S, Gupta S Heart Rhythm. 2021; 18(7):1212-1220.

PMID: 33737232 PMC: 8259123. DOI: 10.1016/j.hrthm.2021.03.016.


The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.

Burashnikov A, Barajas-Martinez H, Hu D, Robinson V, Grunnet M, Antzelevitch C J Cardiovasc Pharmacol. 2020; 76(2):164-172.

PMID: 32453071 PMC: 7416459. DOI: 10.1097/FJC.0000000000000855.


Influence of Amiodarone and Dronedarone on the Force-Interval Dependence of Rat Myocardium.

Kondratieva D, Afanasiev S, Popov S Biomed Res Int. 2018; 2018:4737489.

PMID: 30155479 PMC: 6098862. DOI: 10.1155/2018/4737489.


Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.

Saengklub N, Limprasutr V, Sawangkoon S, Hamlin R, Kijtawornrat A Exp Anim. 2017; 66(3):251-258.

PMID: 28381818 PMC: 5543246. DOI: 10.1538/expanim.17-0002.


References
1.
Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M . Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001; 29(6):1149-53. DOI: 10.1097/00003246-200106000-00011. View

2.
Celestino D, Medei E, Moro S, Elizari M, Sicouri S . Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J Cardiovasc Pharmacol Ther. 2007; 12(3):248-57. DOI: 10.1177/1074248407303225. View

3.
Singh B, Connolly S, Crijns H, Roy D, Kowey P, Capucci A . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357(10):987-99. DOI: 10.1056/NEJMoa054686. View

4.
Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C . In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004; 44(2):244-57. DOI: 10.1097/00005344-200408000-00015. View

5.
Chatelain P, Meysmans L, Matteazzi J, Beaufort P, Clinet M . Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995; 116(3):1949-56. PMC: 1908949. DOI: 10.1111/j.1476-5381.1995.tb16397.x. View